New Stock Update | Haina Pharma Files for Hong Kong IPO

Stock News

Nov 09

Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its listing application to the Hong Kong Stock Exchange (HKEX) Main Board on November 7, with China International Capital Corporation (CICC) acting as the sole sponsor.

According to the prospectus, Haina Pharma operates as an integrated pharmaceutical R&D and manufacturing company, offering CXO services. It also maintains a proprietary product pipeline, primarily commercialized through drug technology transfers.

Per Frost & Sullivan’s report, Haina Pharma ranked second among China’s CXO service providers engaged in drug technology transfers during the track-record period and up to the latest practicable date, based on the total number of approved clinical trials and marketing authorizations. The company also secured the second position in terms of total submitted clinical trial and marketing authorization applications during the same period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105352525"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105352525\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105352525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-09 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105352525","market":"fut","top_or_hot":-1,"title":"New Stock Update | Haina Pharma Files for Hong Kong IPO","media":"Stock News","content":"<p>Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its listing application to the Hong Kong Stock Exchange (HKEX) Main Board on November 7, with China International Capital Corporation (CICC) acting as the sole sponsor.</p>\n<p>According to the prospectus, Haina Pharma operates as an integrated pharmaceutical R&D and manufacturing company, offering CXO services. It also maintains a proprietary product pipeline, primarily commercialized through drug technology transfers.</p>\n<p>Per Frost & Sullivan’s report, Haina Pharma ranked second among China’s CXO service providers engaged in drug technology transfers during the track-record period and up to the latest practicable date, based on the total number of approved clinical trials and marketing authorizations. The company also secured the second position in terms of total submitted clinical trial and marketing authorization applications during the same period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Stock Update | Haina Pharma Files for Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Stock Update | Haina Pharma Files for Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-09 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its listing application to the Hong Kong Stock Exchange (HKEX) Main Board on November 7, with China International Capital Corporation (CICC) acting as the sole sponsor.</p>\n<p>According to the prospectus, Haina Pharma operates as an integrated pharmaceutical R&D and manufacturing company, offering CXO services. It also maintains a proprietary product pipeline, primarily commercialized through drug technology transfers.</p>\n<p>Per Frost & Sullivan’s report, Haina Pharma ranked second among China’s CXO service providers engaged in drug technology transfers during the track-record period and up to the latest practicable date, based on the total number of approved clinical trials and marketing authorizations. The company also secured the second position in terms of total submitted clinical trial and marketing authorization applications during the same period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1105352525","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105352525","pubTimestamp":1762677853,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its listing application to the Hong Kong Stock Exchange (HKEX) Main Board on November 7, with China International...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","BK1515":"抗疫概念"},"translate_title":"新股动态|海纳医药申请香港IPO","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"HEXmain":1},"content_text":"Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its listing application to the Hong Kong Stock Exchange (HKEX) Main Board on November 7, with China International Capital Corporation (CICC) acting as the sole sponsor.\nAccording to the prospectus, Haina Pharma operates as an integrated pharmaceutical R&D and manufacturing company, offering CXO services. It also maintains a proprietary product pipeline, primarily commercialized through drug technology transfers.\nPer Frost & Sullivan’s report, Haina Pharma ranked second among China’s CXO service providers engaged in drug technology transfers during the track-record period and up to the latest practicable date, based on the total number of approved clinical trials and marketing authorizations. The company also secured the second position in terms of total submitted clinical trial and marketing authorization applications during the same period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}